Vitiligo and thyroid disease: a systematic review and meta-analysis

Kang Chih Fan, Ting Hua Yang, Yu Chen Huang

Research output: Contribution to journalReview article

Abstract

Vitiligo is associated with (autoimmune) thyroid disease. However, confounding factors, including type and onset of vitiligo, require elucidation. We conducted a meta-analysis to identify vitiligo patients with increased risk of (autoimmune) thyroid disease. Studies were identified based on searches in PubMed, MEDLINE, Embase, and the Cochrane Library from inception of these databases to August 31st, 2017. Odds ratios (ORs) for the prevalence of (autoimmune) thyroid disease and thyroid antibodies in vitiligo patients were pooled, and subgroup analysis was performed. Thirty-seven studies with 78,714 vitiligo patients met the inclusion criteria. The prevalence of thyroid disease (TD) (OR: 3.932; 95% CI: 2.230–6.933), autoimmune TD (OR: 5.879; 95% CI: 2.682–12.885), anti-thyroperoxidase (TPO) antibody (OR: 3.838; 95% CI: 2.968–4.963), and anti-thyroglobulin antibody (OR: 3.513; 95% CI: 2.346–5.260) was significantly higher in vitiligo patients than in controls. Notably, the prevalence of TD and anti-TPO antibody was significantly higher in patients with non-segmental vitiligo, compared to those with segmental vitiligo. In contrast, the prevalence of TD was significantly lower in early-, compared to the late-onset vitiligo group (OR: 0.333; 95% CI: 0.244–0.453). Physicians should be aware of the increased risk of (autoimmune) thyroid disease in vitiligo patients. We recommend routine screening for anti-thyroid antibodies in vitiligo patients.

Original languageEnglish
Pages (from-to)750-763
Number of pages14
JournalEuropean Journal of Dermatology
Volume28
Issue number6
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Vitiligo
Thyroid Diseases
Autoimmune Diseases
Meta-Analysis
Anti-Idiotypic Antibodies
Odds Ratio
Thyroid Gland
anti-thyroglobulin
PubMed
MEDLINE
Libraries
Databases

Keywords

  • anti-thyroglobulin antibody
  • anti-thyroperoxidase antibody
  • autoimmune thyroid disease
  • meta-analysis
  • thyroid disease
  • vitiligo

ASJC Scopus subject areas

  • Dermatology

Cite this

Vitiligo and thyroid disease : a systematic review and meta-analysis. / Fan, Kang Chih; Yang, Ting Hua; Huang, Yu Chen.

In: European Journal of Dermatology, Vol. 28, No. 6, 01.11.2018, p. 750-763.

Research output: Contribution to journalReview article

Fan, Kang Chih ; Yang, Ting Hua ; Huang, Yu Chen. / Vitiligo and thyroid disease : a systematic review and meta-analysis. In: European Journal of Dermatology. 2018 ; Vol. 28, No. 6. pp. 750-763.
@article{252be276c9f24060b13382c9f5b36191,
title = "Vitiligo and thyroid disease: a systematic review and meta-analysis",
abstract = "Vitiligo is associated with (autoimmune) thyroid disease. However, confounding factors, including type and onset of vitiligo, require elucidation. We conducted a meta-analysis to identify vitiligo patients with increased risk of (autoimmune) thyroid disease. Studies were identified based on searches in PubMed, MEDLINE, Embase, and the Cochrane Library from inception of these databases to August 31st, 2017. Odds ratios (ORs) for the prevalence of (autoimmune) thyroid disease and thyroid antibodies in vitiligo patients were pooled, and subgroup analysis was performed. Thirty-seven studies with 78,714 vitiligo patients met the inclusion criteria. The prevalence of thyroid disease (TD) (OR: 3.932; 95{\%} CI: 2.230–6.933), autoimmune TD (OR: 5.879; 95{\%} CI: 2.682–12.885), anti-thyroperoxidase (TPO) antibody (OR: 3.838; 95{\%} CI: 2.968–4.963), and anti-thyroglobulin antibody (OR: 3.513; 95{\%} CI: 2.346–5.260) was significantly higher in vitiligo patients than in controls. Notably, the prevalence of TD and anti-TPO antibody was significantly higher in patients with non-segmental vitiligo, compared to those with segmental vitiligo. In contrast, the prevalence of TD was significantly lower in early-, compared to the late-onset vitiligo group (OR: 0.333; 95{\%} CI: 0.244–0.453). Physicians should be aware of the increased risk of (autoimmune) thyroid disease in vitiligo patients. We recommend routine screening for anti-thyroid antibodies in vitiligo patients.",
keywords = "anti-thyroglobulin antibody, anti-thyroperoxidase antibody, autoimmune thyroid disease, meta-analysis, thyroid disease, vitiligo",
author = "Fan, {Kang Chih} and Yang, {Ting Hua} and Huang, {Yu Chen}",
year = "2018",
month = "11",
day = "1",
doi = "10.1684/ejd.2018.3449",
language = "English",
volume = "28",
pages = "750--763",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "John Libbey Eurotext",
number = "6",

}

TY - JOUR

T1 - Vitiligo and thyroid disease

T2 - a systematic review and meta-analysis

AU - Fan, Kang Chih

AU - Yang, Ting Hua

AU - Huang, Yu Chen

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Vitiligo is associated with (autoimmune) thyroid disease. However, confounding factors, including type and onset of vitiligo, require elucidation. We conducted a meta-analysis to identify vitiligo patients with increased risk of (autoimmune) thyroid disease. Studies were identified based on searches in PubMed, MEDLINE, Embase, and the Cochrane Library from inception of these databases to August 31st, 2017. Odds ratios (ORs) for the prevalence of (autoimmune) thyroid disease and thyroid antibodies in vitiligo patients were pooled, and subgroup analysis was performed. Thirty-seven studies with 78,714 vitiligo patients met the inclusion criteria. The prevalence of thyroid disease (TD) (OR: 3.932; 95% CI: 2.230–6.933), autoimmune TD (OR: 5.879; 95% CI: 2.682–12.885), anti-thyroperoxidase (TPO) antibody (OR: 3.838; 95% CI: 2.968–4.963), and anti-thyroglobulin antibody (OR: 3.513; 95% CI: 2.346–5.260) was significantly higher in vitiligo patients than in controls. Notably, the prevalence of TD and anti-TPO antibody was significantly higher in patients with non-segmental vitiligo, compared to those with segmental vitiligo. In contrast, the prevalence of TD was significantly lower in early-, compared to the late-onset vitiligo group (OR: 0.333; 95% CI: 0.244–0.453). Physicians should be aware of the increased risk of (autoimmune) thyroid disease in vitiligo patients. We recommend routine screening for anti-thyroid antibodies in vitiligo patients.

AB - Vitiligo is associated with (autoimmune) thyroid disease. However, confounding factors, including type and onset of vitiligo, require elucidation. We conducted a meta-analysis to identify vitiligo patients with increased risk of (autoimmune) thyroid disease. Studies were identified based on searches in PubMed, MEDLINE, Embase, and the Cochrane Library from inception of these databases to August 31st, 2017. Odds ratios (ORs) for the prevalence of (autoimmune) thyroid disease and thyroid antibodies in vitiligo patients were pooled, and subgroup analysis was performed. Thirty-seven studies with 78,714 vitiligo patients met the inclusion criteria. The prevalence of thyroid disease (TD) (OR: 3.932; 95% CI: 2.230–6.933), autoimmune TD (OR: 5.879; 95% CI: 2.682–12.885), anti-thyroperoxidase (TPO) antibody (OR: 3.838; 95% CI: 2.968–4.963), and anti-thyroglobulin antibody (OR: 3.513; 95% CI: 2.346–5.260) was significantly higher in vitiligo patients than in controls. Notably, the prevalence of TD and anti-TPO antibody was significantly higher in patients with non-segmental vitiligo, compared to those with segmental vitiligo. In contrast, the prevalence of TD was significantly lower in early-, compared to the late-onset vitiligo group (OR: 0.333; 95% CI: 0.244–0.453). Physicians should be aware of the increased risk of (autoimmune) thyroid disease in vitiligo patients. We recommend routine screening for anti-thyroid antibodies in vitiligo patients.

KW - anti-thyroglobulin antibody

KW - anti-thyroperoxidase antibody

KW - autoimmune thyroid disease

KW - meta-analysis

KW - thyroid disease

KW - vitiligo

UR - http://www.scopus.com/inward/record.url?scp=85060818165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060818165&partnerID=8YFLogxK

U2 - 10.1684/ejd.2018.3449

DO - 10.1684/ejd.2018.3449

M3 - Review article

C2 - 30698146

AN - SCOPUS:85060818165

VL - 28

SP - 750

EP - 763

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 6

ER -